VERONA PHARMA PLC | |||||||
Date: March 12, 2019 | By: | /s/ Claire Poll | |||||
Name: | Claire Poll | ||||||
Title: | Legal Counsel | ||||||
1 | Details of the person discharging managerial responsibilities/person closely associated | |
a) | Name | David Ebsworth |
2 | Reason for the notification | |
a) | Position/status | Chairman |
b) | Initial notification/Amendment | Initial notification |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
a) | Name | Verona Pharma plc |
b) | LEI | 213800EVI6O6J3TIAL06 |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
a) | Description of the financial instrument, type of instrument Identification code | Ordinary Shares of 5 pence each GB00BYW2KH80 |
b) | Nature of the transaction | David Ebsworth purchased 17,500 Ordinary Shares |
c) | Price(s) and volume(s) | Price(s) : 57.00 pence per Ordinary Share Volume(s) : 17,500 Ordinary Shares |
d) | Aggregated information - Aggregated volume - Price | N/A |
e) | Date of the transaction | 8 March 2019 |
f) | Place of the transaction | London Stock Exchange, AIM |
Verona Pharma plc | Tel: +44 (0)20 3283 4200 |
Jan-Anders Karlsson, Chief Executive Officer | info@veronapharma.com |
Victoria Stewart, Director of Communications | |
Stifel Nicolaus Europe Limited (Nominated Adviser and UK Broker) | Tel: +44 (0) 20 7710 7600 |
Stewart Wallace / Jonathan Senior / Ben Maddison |
1 | Details of the person discharging managerial responsibilities/person closely associated | |
a) | Name | David Ebsworth |
2 | Reason for the notification | |
a) | Position/status | Chairman |
b) | Initial notification/Amendment | Initial notification |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
a) | Name | Verona Pharma plc |
b) | LEI | 213800EVI6O6J3TIAL06 |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
a) | Description of the financial instrument, type of instrument Identification code | Ordinary Shares of 5 pence each GB00BYW2KH80 |
b) | Nature of the transaction | David Ebsworth purchased 43,800 Ordinary Shares |
c) | Price(s) and volume(s) | Price(s) : 57.00 pence per Ordinary Share Volume(s) : 43,800 Ordinary Shares |
d) | Aggregated information - Aggregated volume - Price | N/A |
e) | Date of the transaction | 4 March 2019 |
f) | Place of the transaction | London Stock Exchange, AIM |
Verona Pharma plc | Tel: +44 (0)20 3283 4200 |
Jan-Anders Karlsson, Chief Executive Officer | info@veronapharma.com |
Victoria Stewart, Director of Communications | |
Stifel Nicolaus Europe Limited (Nominated Adviser and UK Broker) | Tel: +44 (0) 20 7710 7600 |
Stewart Wallace / Jonathan Senior / Ben Maddison |
1 | Details of the person discharging managerial responsibilities/person closely associated | |
a) | Name | David Ebsworth |
2 | Reason for the notification | |
a) | Position/status | Chairman |
b) | Initial notification/Amendment | Initial notification |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
a) | Name | Verona Pharma plc |
b) | LEI | 213800EVI6O6J3TIAL06 |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
a) | Description of the financial instrument, type of instrument Identification code | Ordinary Shares of 5 pence each GB00BYW2KH80 |
b) | Nature of the transaction | David Ebsworth purchased 26,300 Ordinary Shares |
c) | Price(s) and volume(s) | Price(s) : 56.30 pence per Ordinary Share Volume(s) : 26,300 Ordinary Shares |
d) | Aggregated information - Aggregated volume - Price | N/A |
e) | Date of the transaction | 6 March 2019 |
f) | Place of the transaction | London Stock Exchange, AIM |
Verona Pharma plc | Tel: +44 (0)20 3283 4200 |
Jan-Anders Karlsson, Chief Executive Officer | info@veronapharma.com |
Victoria Stewart, Director of Communications | |
Stifel Nicolaus Europe Limited (Nominated Adviser and UK Broker) | Tel: +44 (0) 20 7710 7600 |
Stewart Wallace / Jonathan Senior / Ben Maddison |